AC-201 not checked

TWi Biotechnology, Inc. · AC-203

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“The investigational product is formulated as 1% topical ointment”In the company’s words, NCT06073132 on ClinicalTrials.gov
Tested for
Generalized Epidermolysis Bullosa Simplex
Main trialPhase 2/3
“The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.”In the company’s words, NCT06073132 on ClinicalTrials.gov
Other names
AC-203

Other drugs for Generalized Epidermolysis Bullosa Simplex

All 3 drugs for Generalized Epidermolysis Bullosa Simplex

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting 10 Jun 2026 An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Phase 2Completed 27 Oct 2016 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AC-201

Following is part of Solo: you see every change to AC-201 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in